| Similar Articles |
|---|
 |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response.   |
Bio-IT World
June 12, 2002
Kevin Davies |
Variations on a Theme Researchers at Genaissance Pharmaceuticals have outlined the path to creating a comprehensive map of human genomic variation that should ultimately reveal the genetic underpinnings of common diseases. |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
Bio-IT World
February 11, 2005
Kevin Davies |
The Galileo Code In searching 400 years of French-Canadian history for genetic clues to diseases among Quebec's founding population, Genizon BioSciences -- formerly Galileo Genomics -- is rapidly becoming the bio-IT company du jour. |
Fast Company
November 2009
David H. Freedman |
The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens. |
BusinessWeek
June 13, 2005
John Carey |
The NIH's Roadmap for Research Charting the human genome was just the beginning. Now the focus is creating pathways that will lead to practical applications. |
Bio-IT World
September 2005
Mark D. Uehling |
Kings of Genes and Data The speed by which things move at Iceland's deCODE supports the company's claim that it is not only reconnecting the bifurcated worlds of drug discovery and clinical research - it is also internally cross-pollinating ideas between those two realms. |
Wired
November 17, 2007
Thomas Goetz |
23AndMe Will Decode Your DNA for $1,000. Welcome to the Age of Genomics A much-anticipated Silicon Valley startup called 23andMe offers a thorough tour of your genealogy, tracing your DNA back through the eons. |
Bio-IT World
June 17, 2004
Michael A. Goldman |
A Hip Approach to Gene Hunting IntegraGen defines the genetic blueprint of complex human diseases and delivers validated disease markers and therapeutic targets for a better diagnosis and a causal treatment of common diseases, based on its unique genomic analysis expertise. |
Bio-IT World
September 9, 2002
Malorye Branca |
The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Bio-IT World
April 15, 2003
Malorye Branca |
Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease? |
Reason
Aug/Sep 2000
Ronald Bailey |
Strands of Life Book Review: Genome: The Autobiography of a Species in 23 Chapters, by Matt Ridley |
Scientific American
June 2009
Melinda Wenner |
Genetic Copy Variations and Disease A new sense for how variable numbers of genes cause disease. |
CIO
July 15, 2001
Stephanie Overby |
Iceland's Dilemma: Privacy vs. Progress A small Icelandic startup has been granted a 12-year license to create and manage a database of the entire nation's medical and genetic records. Can it make medical history without violating patient privacy? |
Bio-IT World
May 2006
Kevin Davies |
Personalized Medicine's Rosy Picture GlaxoSmithKline's head of genetics research, Allen Roses, says that pharmacogenetics is having a profound impact on the stratifying of patients, the minimization of adverse events, and the expedited passage of drug candidates through clinical trials. |
Bio-IT World
May 2006
Kevin Davies |
Decoding the Genetics of Common Disease Icelandic biopharma deCODE Genetics' Kari Stefansson says his company's search for genes underlying common diseases is not only pushing promising new drug candidates into the clinic but also revealing new insights into the very basis of common disease. |
HHMI Bulletin
May 2012
Sarah C. P. Williams |
Opening the Floodgates Researchers are using exome sequencing -- zeroing in on the genes that encode proteins -- to explore the biology of certain diseases. |
BusinessWeek
May 9, 2005 |
A Genome Pioneer Looks Forward Dr. Francis Collins discusses the end of the Human Genome Project and says an "outpouring of discoveries" is coming soon. |
Bio-IT World
August 15, 2005
Kevin Davies |
TGen's Discovery Pipeline in the Desert At the Translational Genomics Research Institute, researchers have developed an industrial-style informatics strategy and discovery infrastructure that has pinpointed some 25 disease genes in the past 24 months, many of which are pending identification. |
BusinessWeek
November 7, 2005
Catherine Arnst |
How Likely Are You To Get Sick? A new DNA database could gauge your risk for disease. |
Bio-IT World
January 13, 2003
Kari Stefansson |
The Icelandic Man Cometh The founder of deCODE Genetics on Viking DNA, privacy, disease, and aging. |
BusinessWeek
October 23, 2008 |
The Story in Your Genes There's tremendous value in genetic data, but it depends on how deeply you look. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
Salon.com
May 1, 2000
Arthur Allen |
Listening to DNA The genome project is getting the buzz. But the real breakthroughs may come from labs out of the limelight, like Gene Logic. |
American Journal of Nursing
October 2009 |
Pharmacogenomics: Personalizing Drug Therapy Pharmacogenomics is a rapidly growing field of research into the ways in which genetic variation affects drug response. |
Bio-IT World
October 9, 2002
Kevin Davies |
Cracking the 'Druggable Genome' How many potential drug targets are encoded in the human genome? It is a crucial question for every biopharma business. |
IEEE Spectrum
March 2013
Eliza Strickland |
The Gene Machine and Me Ion Torrent's chip-based genome sequencer is cheap, fast, and poised to revolutionize medicine |
Wired
August 2000
Jennifer Hillner |
Area 22 The inside story of the first fully sequenced chromosome. |
Fast Company
September 2000
John Ellis |
The Secret of Life The mapping of the human genome, says Craig Venter, will change science, research, medicine, politics, health insurance, and the way biology looks at the last 3 billion years of evolution. And that's just the beginning. |
Managed Care
August 2004
Thomas Morrow |
10,000 Cells on a Chip Signal Start of New Era of Diagnosis Diseases will soon be defined by biochemical pathways and genetic interactions. Biochips may identify patients likely to respond to therapeutic agents. All of this is a big deal for health plans. |
Bio-IT World
October 14, 2004
Kevin Davies |
Galileo Opts for Illumina Beads Following a successful gene-mapping partnership with one California high-tech company, Montreal-based Galileo Genomics is turning to another to finish the job. |
Chemistry World
June 6, 2007
Simon Hadlington |
Large-Scale Gene Scanning for Common Diseases A multi-center genome scanning project that has analyzed half a million genetic markers in thousands of healthy people and people with a range of common diseases has revealed previously unknown genetic variants of the diseases. |
Bio-IT World
March 10, 2003
Salvatore Salamone |
Common Knowledge Two heads (or more) are better than one, except when they don't share information. That's where knowledge management comes in. |
Bio-IT World
November 14, 2003
Kathy Ordonez |
Targeted Medicine via Molecular Diagnostics Using diagnostics to select and deselect target populations for drug therapy will enable life scientists to make more effective medicines. |
Nurse Practitioner
August 2009
Linda A. Howe |
Pharmacogenomics and management of cardiovascular disease Prior to the completion of the Human Genome Project in 2003, individual responses to medications were usually termed idiosyncrasies. Ethnic differences were not usually seen as genetic variants, as is the case today. |
Managed Care
May 2001
Michael D. Dalzell |
Powerful Opportunities For Good and Greed Genetic advances could spawn incredible improvements in health care. Given public demand, they also pose what may be unmanageable issues of resource use... |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
Wired
November 2002
David Ewing Duncan |
DNA as Destiny DNA is the book of life. It's also the book of death. In the future we'll all be read cover to cover. Here's what it's like to take the world's first top-to-bottom gene scan. |
Managed Care
May 2005
Martin Sipkoff |
Predictive Modeling & Genomics: Marriage of Promise and Risk Integration of predictive modeling and genomic tools means improved technology, enhanced databases, and appropriate legal guidance. |
Bio-IT World
November 14, 2003
Malorye Branca |
Genomics Provides the Kick Inside New tools and business structures show signs of plumping early-stage pipelines. |
Bio-IT World
July 11, 2002
Malorye Branca |
Deep Sequence Diving Like sailors of old, genomic data miners dream of discovering riches and fame. Given the recent improvements in analytics -- and a little more time -- they just might succeed. |
Salon.com
February 13, 2001
Arthur Allen |
Size doesn't matter As scientists unveil the human genome findings, it turns out we have a lot fewer genes than we'd thought, and not many more than a fruit fly... |
Bio-IT World
Dec 2006/Jan 2007
Kevin Davies |
The One Percent Difference New research reveals a shocking new layer of human genome variation with profound implications for the future of genomic analysis and personalized medicine. |
Bio-IT World
February 10, 2003
Mark D. Uehling |
Decoding Estonia The former Soviet republic aims to use IT and culture to build a national gene database. It is modestly funded but is already being noticed by scientists and industry. |
Pharmaceutical Executive
June 1, 2011 |
To Screen or Not to Screen? What do our genetics tell us about our predisposition to certain diseases? What does this mean for pharmaceutical companies? |
The Motley Fool
March 18, 2008
Brian Orelli |
The Nuts and Bolts of Drug Research Merck just released a pair of papers detailing the network of proteins that are linked to obesity, but the pharmaceutical company won't benefit much financially from its studies. So who will? |
Bio-IT World
August 15, 2005
Robert M. Frederickson |
What's 'Post' About Postgenomic? Bioinformatics tools can help organize and study genomic sequences that were discovered in the '90s. The tools help with tasks like analyzing gene expression, predicting protein structure and function, and establishing networks of interacting protein in cells. |
Managed Care
November 2006
Maureen Glabman |
Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
